Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Receptor Modulator ◽

Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

10.1158/1538-7445.sabcs19-p5-11-02 ◽

2020 ◽

Author(s):

Mario Campone ◽

Aditya Bardia ◽

Gary A Ulaner ◽

Sarat Chandarlapaty ◽

Alice Gosselin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Abstract PD8-08: A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1

10.1158/1538-7445.sabcs20-pd8-08 ◽

2021 ◽

Author(s):

Hannah M Linden ◽

Mario Campone ◽

Aditya Bardia ◽

Gary A Ulaner ◽

Alice Gosselin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Cancer Therapies ◽

Anti Cancer ◽

Er Positive ◽

Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

10.1158/1538-7445.sabcs18-ot1-03-01 ◽

2019 ◽

Author(s):

G Curigliano ◽

S Cresta ◽

Y-S Yap ◽

D Juric ◽

FP Duhoux ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

10.1158/1538-7445.sabcs19-pd7-07 ◽

2020 ◽

Author(s):

Virginia Kaklamani ◽

Aditya Bardia ◽

Sharon Wilks ◽

Amy Weise ◽

Donald Richards ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Final Analysis ◽

Phase 1 Study ◽

Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-10-07 ◽

2018 ◽

Author(s):

M Campone ◽

J Sachdev ◽

GV Bianchi ◽

JT Beck ◽

N Martínez-Jáñez ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Randomized Phase Ii ◽

116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC)

Annals of Oncology ◽

10.1093/annonc/mdw577 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Cited By ~ 3

Author(s):

S-A. Im ◽

H. Mukai ◽

I.H. Park ◽

N. Masuda ◽

C. Shimizu ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Asian Women ◽

First Line ◽

Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs20-pd1-09 ◽

2021 ◽

Author(s):

Ian Krop ◽

Kan Yonemori ◽

Shunji Takahashi ◽

Kenichi Inoue ◽

Takahiro Nakayama ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Antibody Drug Conjugate ◽

Safety And Efficacy ◽

Epidermal Growth ◽

Antibody Drug

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Current Medical Research and Opinion ◽

10.1185/03007995.2016.1157060 ◽

2016 ◽

Vol 32 (5) ◽

pp. 959-965 ◽

Cited By ~ 11

Author(s):

T. Bell ◽

J.P. Crown ◽

I. Lang ◽

H. Bhattacharyya ◽

G. Zanotti ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Molecular Medicine Reports ◽

10.3892/mmr.2018.8580 ◽

2018 ◽

Cited By ~ 1

Author(s):

Seung Taek Lim ◽

Ye Won Jeon ◽

Hongki Gwak ◽

Se Young Kim ◽

Young Jin Suh

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Breast Cancer Cells ◽

Growth Factor Receptor ◽

Anticancer Effects ◽

Epidermal Growth ◽

Positive Breast Cancer

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05125-4 ◽

2019 ◽

Vol 174 (3) ◽

pp. 719-729 ◽

Cited By ~ 56

Author(s):

H. S. Rugo ◽

R. S. Finn ◽

V. Diéras ◽

J. Ettl ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽